High-tech advances, such as PET scanning, offer new insight into the role cholesterol plays in both the amyloid cascade and vascular models of the development of Alzheimer’s dementia.
Cholesterol and Alzheimer’s Disease
Millions suffer from Alzheimer’s disease. And, the available and foreseeable treatments are disappointing at best. Given the absence of disease-modifying treatments, there has been growing interest in effective strategies for the prevention of the disease in the first place. Even if we were able to just delay the onset by as little as one year, we could potentially prevent more than nine million cases over the next 40 years.
Once cognitive functions are lost in Alzheimer’s disease patients, they may be lost forever. Consequently, prevention, rather than a cure for Alzheimer’s Disease, appears as a more realistic strategy to offset the catastrophic impact of this dementia.
Considerable evidence now indicates that Alzheimer’s Disease is primarily a vascular disorder, based on a number of lines of evidence that point toward impaired circulation of blood to the brain.
Vascular risk factors, such as high cholesterol, can be thought of as a ticking time bomb to Alzheimer’s Disease. What’s bad for the heart may be bad for the mind.
Traditionally, there have been two competing theories for the cause of Alzheimer’s: the amyloid cascade model that implicates the buildup of amyloid plaques within the brain, and the vascular model, that argues that it is the lack of adequate blood flow to the brain due to atherosclerosis. We now realize they are not mutually exclusive, and that arterial disease can set up a vicious cycle, in which atherosclerotic plaques in the arteries may contribute to Alzheimer’s plaques in the brain.
Although at times portrayed as tantamount to poison, cholesterol is an essential structural component of all of our cells, but if there’s too much, it can become a major factor contributing to various diseases, including coronary heart disease, stroke, and neurodegenerative diseases, like Alzheimer’s. Too much cholesterol in our blood is unanimously recognized to be a risk factor for the development Alzheimer’s disease, and cholesterol may play an active role in the progression of Alzheimer’s as well.
Autopsy studies have found that Alzheimer’s brains have significantly more cholesterol than normal brains, and it specifically appears to accumulate in the Alzheimer brain plaques. We used to think the pool of cholesterol in the brain was separate from the pool we had in our blood, but there is now growing evidence to the contrary. For example, LDL may be able to cross the blood–brain barrier into the brain. So, a high-fat diet may not only increase cholesterol levels in the blood, but also the influx of cholesterol into the central nervous system.
In addition, having high cholesterol may even damage the blood brain barrier itself, and allow for even more cholesterol to flow into the brain, providing the missing link between high cholesterol and Alzheimer’s. Individuals with higher cholesterol levels at midlife have a higher risk of going on to develop Alzheimer’s disease. Cholesterol over 250 could potentially triple the odds of Alzheimer’s.
And now we have high-tech PET scanning of the brain that can directly correlate the amount of so-called bad cholesterol in our blood with the amount of amyloid build up in our brains. You can do it right in a petri dish. Adding cholesterol makes them churn out more the amyloid that makes up Alzheimer plaques, whereas removing cholesterol can decrease the levels of amyloid released from the cells.
In addition, amyloid degradation is less efficient in a high cholesterol environment. Cholesterol can then help seed the clumping of the amyloid. Using an electron microscope, you can see the clustering of amyloid fibers on and around little microcrystals of cholesterol.
Once in the brain, cholesterol can also undergo auto-oxidation, causing the formation of highly toxic free radicals. So, having high cholesterol levels in the blood is thought to increase the risk of dementia, not only by inducing atherosclerosis and impairing blood flow, but they may also directly affect neurodegeneration within the brain. In conclusion, excess dietary cholesterol could, in principle, contribute to the development of Alzheimer’s disease, and the evidence linking high cholesterol to Alzheimer’s appears to be steadily mounting.
Of course, some of this work was paid for by drug companies hoping to capitalize on Alzheimer’s with cholesterol-lowering statin drugs. Ironic, since statins themselves can cause cognitive impairment. Though rare, statin side-effects may include short- and long-term memory loss, behavioral changes, impaired concentration and attention, paranoia, and anxiety, as early as five days after starting the drugs, but sometimes even months later, though folks should recover within a month of stopping the drugs.
A better strategy may be to change the lifestyle factors that lead to the high cholesterol in the first place, in particular, reducing saturated fat in the diet, but it’s not enough for us to just tell our individual patients. Systematic implementation of educational campaigns promoting radical changes in cultural and societal values may be necessary to adopt Alzheimer’s defeating strategies by patients in a broader sense, and such actions “may provide potentially huge dividends by preventing both cardiovascular disease and dementia,” two of our leading causes of death.
To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video. This is just an approximation of the audio contributed by Katie Schloer.
Please consider volunteering to help out on the site.
- D E Barnes, K Yaffe. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011 Sep;10(9):819-28.
- J C de la Torre. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci. 2002 Nov;977:196-215.
- M Simons, P Keller, J Dichgans, J B Schulz. Cholesterol and Alzheimer's disease: is there a link? Neurology. 2001 Sep 25;57(6):1089-93.
- J C de la Torre. The vascular hypothesis of Alzheimer's disease: bench to bedside and beyond. Neurodegener Dis. 2010;7(1-3):116-21.
- J C de la Torre. Vascular risk factors: a ticking time bomb to Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):551-9.
- D L Sparks. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease? Ann N Y Acad Sci. 1997 Sep 26;826:128-46.
- J Marx. Bad for the Heart, Bad For the Mind? Science 19 October 2001: Vol. 294 no. 5542 pp. 508-509.
- M Simons, P Keller, B De Strooper, K Beyreuther, C G Dotti, K Simons. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6460-4.
- R N Kalaria, R Akinyemi, M Ihara. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012 Nov 15;322(1-2):141-7.
- A Mathew, Y Yoshida, T Maekawa, D S Kumar. Alzheimer's disease: Cholesterol a menace? Brain Research Bulletin Volume 86, Issues 1–2, 10 August 2011, Pages 1–12.
- A E Roher, S L Tyas, C L Maarouf, I D Daugs, T A Kokjohn M R Emmerling, Z Garami, M Belohlavek, M N Sabbagh, L I Sue, T G Beach. Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Alzheimers Dement. 2011 Jul;7(4):436-44.
- J E Vance, H Hayashi, B Karten. Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol. 2005 Apr;16(2):193-212.
- M Kivipelto, E L Helkala, T Hannien, M P Laakso, M Hallikainen, K Alhainen, H Soininen, J Tuomilehto, A Nissinen. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 2001 Jun 26;56(12):1683-9.
- I L Notkola, R Sulkava, J Pekkanen, T Erkinjuntti, C Ehnholm, P Kivinen, J Tuomilehto, A Nissinen. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17(1):14-20.
- R Altman, J C Rutledge. The vascular contribution to Alzheimer's disease. Clin Sci (Lond). 2010 Aug 5;119(10):407-21.
- J D Buxbaum, N S M Geoghagen, L T Friedhoff. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. Journal of Alzheimer's Disease, vol. 3, no. 2, pp. 221-229, 2001 14 May 2001 | Accepted 14 May 2001 | Published 2001.
- R J Kelleher, R L Soiza. Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder? Am J Cardiovasc Dis. 2013 Nov 1;3(4):197-226.
- L Puglielli, R E Tanzi, D M Kovacs. Alzheimer's disease: the cholesterol connection. Nat Neurosci. 2003 Apr;6(4):345-51.
- J R Harris, N G Milton. Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Subcell Biochem. 2010;51:47-75.
- C H Rojas-Fernandez, J C Cameron. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012 Apr;46(4):549-57.
- B Reed, S Villeneuve, W Mack, C DeCarli, H C Chui, W Jagust. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014 Feb;71(2):195-200.
- Corsinovi L, Biasi F, Poli G, Leonarduzzi G, Isaia G. Dietary lipids and their oxidized products in Alzheimer's disease. Mol Nutr Food Res. 2011 Sep;55 Suppl 2:S161-72. doi: 10.1002/mnfr.201100208. Epub 2011 Aug 31. PMID: 21954186.
Images thanks to geralt via Pixabay.
Millions suffer from Alzheimer’s disease. And, the available and foreseeable treatments are disappointing at best. Given the absence of disease-modifying treatments, there has been growing interest in effective strategies for the prevention of the disease in the first place. Even if we were able to just delay the onset by as little as one year, we could potentially prevent more than nine million cases over the next 40 years.
Once cognitive functions are lost in Alzheimer’s disease patients, they may be lost forever. Consequently, prevention, rather than a cure for Alzheimer’s Disease, appears as a more realistic strategy to offset the catastrophic impact of this dementia.
Considerable evidence now indicates that Alzheimer’s Disease is primarily a vascular disorder, based on a number of lines of evidence that point toward impaired circulation of blood to the brain.
Vascular risk factors, such as high cholesterol, can be thought of as a ticking time bomb to Alzheimer’s Disease. What’s bad for the heart may be bad for the mind.
Traditionally, there have been two competing theories for the cause of Alzheimer’s: the amyloid cascade model that implicates the buildup of amyloid plaques within the brain, and the vascular model, that argues that it is the lack of adequate blood flow to the brain due to atherosclerosis. We now realize they are not mutually exclusive, and that arterial disease can set up a vicious cycle, in which atherosclerotic plaques in the arteries may contribute to Alzheimer’s plaques in the brain.
Although at times portrayed as tantamount to poison, cholesterol is an essential structural component of all of our cells, but if there’s too much, it can become a major factor contributing to various diseases, including coronary heart disease, stroke, and neurodegenerative diseases, like Alzheimer’s. Too much cholesterol in our blood is unanimously recognized to be a risk factor for the development Alzheimer’s disease, and cholesterol may play an active role in the progression of Alzheimer’s as well.
Autopsy studies have found that Alzheimer’s brains have significantly more cholesterol than normal brains, and it specifically appears to accumulate in the Alzheimer brain plaques. We used to think the pool of cholesterol in the brain was separate from the pool we had in our blood, but there is now growing evidence to the contrary. For example, LDL may be able to cross the blood–brain barrier into the brain. So, a high-fat diet may not only increase cholesterol levels in the blood, but also the influx of cholesterol into the central nervous system.
In addition, having high cholesterol may even damage the blood brain barrier itself, and allow for even more cholesterol to flow into the brain, providing the missing link between high cholesterol and Alzheimer’s. Individuals with higher cholesterol levels at midlife have a higher risk of going on to develop Alzheimer’s disease. Cholesterol over 250 could potentially triple the odds of Alzheimer’s.
And now we have high-tech PET scanning of the brain that can directly correlate the amount of so-called bad cholesterol in our blood with the amount of amyloid build up in our brains. You can do it right in a petri dish. Adding cholesterol makes them churn out more the amyloid that makes up Alzheimer plaques, whereas removing cholesterol can decrease the levels of amyloid released from the cells.
In addition, amyloid degradation is less efficient in a high cholesterol environment. Cholesterol can then help seed the clumping of the amyloid. Using an electron microscope, you can see the clustering of amyloid fibers on and around little microcrystals of cholesterol.
Once in the brain, cholesterol can also undergo auto-oxidation, causing the formation of highly toxic free radicals. So, having high cholesterol levels in the blood is thought to increase the risk of dementia, not only by inducing atherosclerosis and impairing blood flow, but they may also directly affect neurodegeneration within the brain. In conclusion, excess dietary cholesterol could, in principle, contribute to the development of Alzheimer’s disease, and the evidence linking high cholesterol to Alzheimer’s appears to be steadily mounting.
Of course, some of this work was paid for by drug companies hoping to capitalize on Alzheimer’s with cholesterol-lowering statin drugs. Ironic, since statins themselves can cause cognitive impairment. Though rare, statin side-effects may include short- and long-term memory loss, behavioral changes, impaired concentration and attention, paranoia, and anxiety, as early as five days after starting the drugs, but sometimes even months later, though folks should recover within a month of stopping the drugs.
A better strategy may be to change the lifestyle factors that lead to the high cholesterol in the first place, in particular, reducing saturated fat in the diet, but it’s not enough for us to just tell our individual patients. Systematic implementation of educational campaigns promoting radical changes in cultural and societal values may be necessary to adopt Alzheimer’s defeating strategies by patients in a broader sense, and such actions “may provide potentially huge dividends by preventing both cardiovascular disease and dementia,” two of our leading causes of death.
To see any graphs, charts, graphics, images, and quotes to which Dr. Greger may be referring, watch the above video. This is just an approximation of the audio contributed by Katie Schloer.
Please consider volunteering to help out on the site.
- D E Barnes, K Yaffe. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011 Sep;10(9):819-28.
- J C de la Torre. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci. 2002 Nov;977:196-215.
- M Simons, P Keller, J Dichgans, J B Schulz. Cholesterol and Alzheimer's disease: is there a link? Neurology. 2001 Sep 25;57(6):1089-93.
- J C de la Torre. The vascular hypothesis of Alzheimer's disease: bench to bedside and beyond. Neurodegener Dis. 2010;7(1-3):116-21.
- J C de la Torre. Vascular risk factors: a ticking time bomb to Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):551-9.
- D L Sparks. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease? Ann N Y Acad Sci. 1997 Sep 26;826:128-46.
- J Marx. Bad for the Heart, Bad For the Mind? Science 19 October 2001: Vol. 294 no. 5542 pp. 508-509.
- M Simons, P Keller, B De Strooper, K Beyreuther, C G Dotti, K Simons. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6460-4.
- R N Kalaria, R Akinyemi, M Ihara. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012 Nov 15;322(1-2):141-7.
- A Mathew, Y Yoshida, T Maekawa, D S Kumar. Alzheimer's disease: Cholesterol a menace? Brain Research Bulletin Volume 86, Issues 1–2, 10 August 2011, Pages 1–12.
- A E Roher, S L Tyas, C L Maarouf, I D Daugs, T A Kokjohn M R Emmerling, Z Garami, M Belohlavek, M N Sabbagh, L I Sue, T G Beach. Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Alzheimers Dement. 2011 Jul;7(4):436-44.
- J E Vance, H Hayashi, B Karten. Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol. 2005 Apr;16(2):193-212.
- M Kivipelto, E L Helkala, T Hannien, M P Laakso, M Hallikainen, K Alhainen, H Soininen, J Tuomilehto, A Nissinen. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 2001 Jun 26;56(12):1683-9.
- I L Notkola, R Sulkava, J Pekkanen, T Erkinjuntti, C Ehnholm, P Kivinen, J Tuomilehto, A Nissinen. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17(1):14-20.
- R Altman, J C Rutledge. The vascular contribution to Alzheimer's disease. Clin Sci (Lond). 2010 Aug 5;119(10):407-21.
- J D Buxbaum, N S M Geoghagen, L T Friedhoff. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. Journal of Alzheimer's Disease, vol. 3, no. 2, pp. 221-229, 2001 14 May 2001 | Accepted 14 May 2001 | Published 2001.
- R J Kelleher, R L Soiza. Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder? Am J Cardiovasc Dis. 2013 Nov 1;3(4):197-226.
- L Puglielli, R E Tanzi, D M Kovacs. Alzheimer's disease: the cholesterol connection. Nat Neurosci. 2003 Apr;6(4):345-51.
- J R Harris, N G Milton. Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Subcell Biochem. 2010;51:47-75.
- C H Rojas-Fernandez, J C Cameron. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012 Apr;46(4):549-57.
- B Reed, S Villeneuve, W Mack, C DeCarli, H C Chui, W Jagust. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014 Feb;71(2):195-200.
- Corsinovi L, Biasi F, Poli G, Leonarduzzi G, Isaia G. Dietary lipids and their oxidized products in Alzheimer's disease. Mol Nutr Food Res. 2011 Sep;55 Suppl 2:S161-72. doi: 10.1002/mnfr.201100208. Epub 2011 Aug 31. PMID: 21954186.
Images thanks to geralt via Pixabay.
Republishing "Cholesterol and Alzheimer’s Disease"
You may republish this material online or in print under our Creative Commons licence. You must attribute the article to NutritionFacts.org with a link back to our website in your republication.
If any changes are made to the original text or video, you must indicate, reasonably, what has changed about the article or video.
You may not use our material for commercial purposes.
You may not apply legal terms or technological measures that restrict others from doing anything permitted here.
If you have any questions, please Contact Us
Cholesterol and Alzheimer’s Disease
LicenseCreative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Content URLDoctor's Note
I’ve since discussed the associated breast cancer risks (Statin Cholesterol Drugs and Invasive Breast Cancer) and the surprisingly low level of effectiveness (The Actual Benefit of Diet vs. Drugs).
Thankfully, the same diet that can protect the heart may protect the brain:
- Alzheimer’s Disease: Grain Brain or Meathead?
- Preventing Alzheimer’s with Lifestyle Changes
- Preventing Alzheimer’s Disease with Diet
- Preventing Alzheimer’s Disease with Plants
- Reducing Glycotoxin Intake to Prevent Alzheimer’s
- Alzheimer’s May Start Decades Before Diagnosis
- Alzheimer’s and Atherosclerosis of the Brain
Wait a second, though, what about “Grain Brain”? Check out The Problem with David Perlmutter, the Grain Brain Doctor.
In 2018, I did a new video on this topic: Oxidized Cholesterol as a Cause of Alzheimer’s Disease. Also check out its follow-up, How to Reduce Cholesterol Oxidation. And in 2023, I added another video you might be interested in: The Role of Endotoxins in Alzheimer’s and Dementia.
For all of the latest videos on cholesterol, see the topic page.
If you haven't yet, you can subscribe to our free newsletter. With your subscription, you'll also get notifications for just-released blogs and videos. Check out our information page about our translated resources.